Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Recurrence 1Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cetuximab 5Irinotecan 3Gemcitabine 2tivozanib 1neratinib 1lorlatinib 1liposomal doxorubicin 1encorafenib 1binimetinib 1Taxes 1Secretin 1Paclitaxel 1PX-866 1Oxaliplatin 1Lomustine 1Leucovorin 1Fluorouracil 1Doxorubicin 1Carboplatin 1Capecitabine 1CB-839 1CA-19-9 Antigen 1Bevacizumab 1Aspirin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × PX-866 × Gastrointestinal × Clear all
NCT01252628 2018-05-16

Phase 1 and 2 Study of PX-866 and Cetuximab

Seagen Inc.

Phase 1/2 Completed
178 enrolled
Gastrointestinal

Carcinoma, Squamous Cell, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡